Sterne Kessler Goldstein Fox

Reexamination Practice of Biotech/Pharma Patents In Group Art Unit 3991

Today we announced the publication of the first paper to provide an in-depth analysis of patent reexamination in the biotechnology, chemical, and pharmaceutical industries, an increasingly significant patent enforcement source and rapidly developing area of patent litigation practice. To read the full press release click here.

This paper addresses reexamination practice of patents in the Biotechnology/Pharmaceutical arts, specifically Group Art Unit 3991 (AU 3991) of the Central Reexamination Unit (CRU) of the United States Patent and Trademark Office (USPTO). To read the full paper download the PDF above.